Damora Therapeutics (DMRA) Preferred Shares (2025 - 2026)
Damora Therapeutics posted quarterly Preferred Shares of $117.6 million for Q1 2026, little changed on a QoQ basis from $117.6 million in Q4 2025.
Damora Therapeutics (DMRA) has 2 years of Preferred Shares data on file, last reported at $117.6 million in Q1 2026.
- For the quarter ending Q1 2026, Preferred Shares changed N/A year-over-year to $117.6 million; the trailing twelve-month figure through Mar 2026 stood at $117.6 million (changed N/A YoY), and the FY2025 full-year result was $117.6 million, changed N/A from the prior year.
- Preferred Shares for Q1 2026 stood at $117.6 million, roughly flat from $117.6 million in the prior quarter.
- Across five years, Preferred Shares topped out at $117.6 million in Q4 2025 and bottomed at $117.6 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | 117.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 117.62 Mn |
| Dec 31, 2025 | 117.62 Mn |